BR112017020948A2 - composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão - Google Patents

composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão

Info

Publication number
BR112017020948A2
BR112017020948A2 BR112017020948-9A BR112017020948A BR112017020948A2 BR 112017020948 A2 BR112017020948 A2 BR 112017020948A2 BR 112017020948 A BR112017020948 A BR 112017020948A BR 112017020948 A2 BR112017020948 A2 BR 112017020948A2
Authority
BR
Brazil
Prior art keywords
fusion protein
agent
preparing
pharmaceutical composition
treating
Prior art date
Application number
BR112017020948-9A
Other languages
English (en)
Inventor
Beom Kim Seong
Yoon Jung Hyei
Woo Yang Seok
Sang Kwon Hyuk
Kang Jae-Hoon
Original Assignee
Ildong Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharm Co., Ltd. filed Critical Ildong Pharm Co., Ltd.
Publication of BR112017020948A2 publication Critical patent/BR112017020948A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

a presente invenção refere-se a uma composição farmacêutica para prevenir e tratar doenças oculares, que compreende, uma proteína de fusão em que um peptídeo de penetração no tecido é fusionado a um agente anti-fator de crescimento endotelial vascular (anti-vegf). a invenção compreende ainda um método para preparar um anti-vegf, que supera a resistência e tem eficácia melhorada e um método para tratar doenças oculares, que compreende administrar uma dose efetiva da proteína de fusão; e uso da proteína de fusão de acordo com a presente invenção para preparar um agente para tratar doenças oculares.
BR112017020948-9A 2015-03-31 2016-03-30 composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão BR112017020948A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150045684 2015-03-31
KR10-2015-0045684 2015-03-31
PCT/KR2016/003254 WO2016159652A1 (ko) 2015-03-31 2016-03-30 조직투과성 펩타이드와 항-혈관 내피세포 성장인자 제제가 융합된 융합단백질을 유효성분으로 포함하는 안질환 예방 및 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112017020948A2 true BR112017020948A2 (pt) 2018-07-10

Family

ID=57004803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020948-9A BR112017020948A2 (pt) 2015-03-31 2016-03-30 composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão

Country Status (11)

Country Link
US (2) US11052130B2 (pt)
EP (2) EP3278810A4 (pt)
JP (1) JP6836512B2 (pt)
KR (1) KR101846306B1 (pt)
CN (1) CN108348572B (pt)
AU (1) AU2016241499B2 (pt)
BR (1) BR112017020948A2 (pt)
CA (1) CA2981145C (pt)
MX (1) MX2017012506A (pt)
RU (1) RU2712623C2 (pt)
WO (1) WO2016159652A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561707B2 (en) 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3278810A4 (en) 2015-03-31 2018-11-21 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
WO2017130194A1 (en) * 2016-01-25 2017-08-03 Rappaport Family Institute For Research In The Medical Sciences Semaphorin 3c variants, compositions comprising said variants and methods of use thereof in treating eye diseases
KR20210021299A (ko) * 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
WO2019240429A1 (ko) * 2018-06-14 2019-12-19 (주) 에빅스젠 세포 투과 펩티드 및 아데노신 탈아미노화효소의 융합 단백질을 포함하는 중증복합면역결핍증 치료용 약학적 조성물
WO2021046538A1 (en) * 2019-09-06 2021-03-11 United States Government As Represented By The Department Of Veterans Affairs Methods and systems for self-administered measurement of critical flicker frequency (cff)
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113384715B (zh) * 2021-06-03 2023-08-04 上海市第十人民医院 一种含有细胞穿透肽融合蛋白的抗vegf药物及其制备方法和应用
EP4368203A1 (en) * 2021-07-05 2024-05-15 Wuhan Neurophth Biotechnology Limited Company Construction and use of anti-vegf antibody in-vivo expression system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US20070071756A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US8877186B2 (en) 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN101951925A (zh) * 2008-02-20 2011-01-19 建新公司 血管发生抑制
FI121959B (fi) * 2008-05-09 2011-06-30 Pirjo Laakkonen Aivokasvaimiin hakeutuva peptidi
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
RU2548807C2 (ru) * 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
CN102869384B (zh) * 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
CN102002104A (zh) 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
JP6121904B2 (ja) * 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP3000825A4 (en) * 2013-05-23 2017-02-08 Ajou University Industry-Academic Cooperation Foundation Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein
RU2623213C1 (ru) 2013-09-19 2017-06-23 Филипс Лайтинг Холдинг Б.В. Компактное устройство преобразования напряжения с непрерывным выходным диапазоном регулирования
KR102157618B1 (ko) 2013-10-21 2020-09-18 주식회사 아이티엘 서빙셀별로 듀플렉스 방식을 달리하는 무선 통신 시스템에서 통신을 수행하는 장치 및 그 방법
EP3278810A4 (en) 2015-03-31 2018-11-21 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused

Also Published As

Publication number Publication date
MX2017012506A (es) 2018-06-27
EP3973977A1 (en) 2022-03-30
CN108348572A (zh) 2018-07-31
AU2016241499A1 (en) 2017-11-09
US20180133288A1 (en) 2018-05-17
AU2016241499B2 (en) 2020-12-17
US11738064B2 (en) 2023-08-29
US11052130B2 (en) 2021-07-06
US20210220436A1 (en) 2021-07-22
CA2981145C (en) 2021-05-11
KR20160117329A (ko) 2016-10-10
RU2712623C2 (ru) 2020-01-30
WO2016159652A1 (ko) 2016-10-06
JP2018515435A (ja) 2018-06-14
RU2017137735A (ru) 2019-04-30
JP6836512B2 (ja) 2021-03-03
EP3278810A1 (en) 2018-02-07
RU2017137735A3 (pt) 2019-09-11
CA2981145A1 (en) 2016-10-06
EP3278810A4 (en) 2018-11-21
KR101846306B1 (ko) 2018-05-18
CN108348572B (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
WO2016042163A3 (en) Ophthalmic drug compositions
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
MX2018002524A (es) Composicion farmaceutica que contiene, como ingrediente activo, proteina de fusion en la que el peptido de tumor-penetrante y el agente anti-angiogenesis se funden, para prevenir y tratar el cancer o enfermedades relacionadas a la angiogenesis.
PH12019500423A1 (en) Pharmaceutical composition
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112015019039A8 (pt) compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
BR112017020132A2 (pt) métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição
BR112015003658A2 (pt) formulações de lipossomas
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements